Amylin receptor 2 (AMY2 receptor)

Amylin receptor 2 is a heterodimeric G protein-coupled receptor formed by the combination of the calcitonin receptor (CTR) with receptor activity-modifying protein 2 (RAMP2). It belongs to the class B family of GPCRs known as calcitonin receptors. The primary endogenous ligand is amylin, a pancreatic peptide hormone involved in regulating appetite, satiety, and glucose metabolism. Amylin also synergizes with other metabolic hormones such as glucagon-like peptide 1. The amylin receptors exist as three subtypes—AMY1, AMY2, and AMY3—depending on which RAMP partners with CTR; specifically, AMY2 consists of CTR plus RAMP2. These complexes can also respond variably to related peptides like calcitonins or CGRP. Amylin mimetics such as pramlintide have been developed for therapeutic use in diabetes. Dual agonists targeting both amylin and calcitonin receptors are under investigation for obesity treatment. There is evidence implicating amylin receptors—including subtype 3—in neurodegenerative diseases like Alzheimer’s disease due to their interaction with amyloidogenic peptides such as Aβ. Activation of these receptors triggers intracellular signaling via G proteins—primarily stimulating adenylyl cyclase through Gs proteins—which leads to downstream physiological effects including reduced food intake and improved glycemic control. In summary, Amylin receptor 2 is an important therapeutic target within metabolic diseases such as obesity and type 2 diabetes mellitus; it may also play roles in migraine pathophysiology and neurodegeneration.

Other names

AMY2 receptorAMYR2Calcitonin receptor/RAMP2 complex

Agonists bind to the amylin receptor 2, activating Gs protein signaling pathways that stimulate adenylyl cyclase, leading to increased cAMP production. This results in modulation of appetite, glucose regulation, and other metabolic effects.